Vaxcyte, Inc. Enters Material Definitive Agreement
Ticker: PCVX · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
Related Tickers: PCVX
TL;DR
VAX just signed a big deal, details TBD.
AI Summary
On September 24, 2025, Vaxcyte, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement or any associated dollar amounts or parties involved.
Why It Matters
This filing indicates a significant new contract or partnership for Vaxcyte, which could impact its future development and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement.
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- September 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- San Carlos, California (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Vaxcyte, Inc. on September 24, 2025?
The filing states that Vaxcyte, Inc. entered into a material definitive agreement on September 24, 2025, but does not provide specific details about the agreement itself.
Are there any other parties involved in this material definitive agreement?
The filing does not specify the other parties involved in the material definitive agreement.
Were any dollar amounts or financial commitments disclosed in relation to this agreement?
No dollar amounts or financial commitments related to the material definitive agreement were disclosed in this filing.
Does this agreement represent a new partnership, acquisition, or licensing deal?
The filing does not specify whether the agreement is a partnership, acquisition, licensing deal, or any other type of arrangement.
When was this agreement officially filed or reported?
This Form 8-K was filed as of September 30, 2025, reporting the earliest event on September 24, 2025.
Filing Stats: 757 words · 3 min read · ~3 pages · Grade level 14.9 · Accepted 2025-09-30 09:06:36
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq Sto
Filing Documents
- pcvx-20250924.htm (8-K) — 27KB
- 0001649094-25-000102.txt ( ) — 143KB
- pcvx-20250924.xsd (EX-101.SCH) — 2KB
- pcvx-20250924_lab.xml (EX-101.LAB) — 22KB
- pcvx-20250924_pre.xml (EX-101.PRE) — 13KB
- pcvx-20250924_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On September 24, 2025 (the "Effective Date"), Vaxcyte, Inc. (the "Company") entered into a Master Services Agreement (the "Agreement") with Patheon Manufacturing Services LLC ("Patheon"), part of Thermo Fisher Scientific. Under the Agreement, Patheon will formulate, fill, inspect, package, label, test, manufacture and supply drug product for the Company at Patheon's facility in Greenville, North Carolina. Pursuant to the Agreement, the Company has agreed to order from Patheon certain binding minimum amounts of drug product based on certain binding forecast periods at certain established prices, which prices may be subject to adjustment. Pursuant to the Agreement, the Company shall also pay Patheon for certain technology transfer activities and reimburse Patheon for certain out-of-pocket capital expenditures. The Agreement has an initial term of 15 years from the Effective Date and will automatically renew for additional three-year periods unless either party provides notice of non-renewal before the end of the then existing term, subject to completion of ongoing services. The Company may terminate the Agreement for convenience upon prior written notice or upon the occurrence of certain customary conditions. Either party may terminate the Agreement if (i) there are certain uncured legal or regulatory violations by the other party; (ii) the other party is subject to any insolvency event, declares bankruptcy, or undergoes similar proceedings; or (iii) there is any uncured material breach of the Agreement by the other party. The parties may also mutually agree to terminate the Agreement for any reason. If the Agreement is terminated by the Company for (i) convenience and not for cause, the Company shall pay Patheon the greater of a fixed dollar amount in the mid-eight-figures and an amount based on the then-current binding forecast, plus certain capital expenditure commitments; or (ii) Program Failure (as define
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: September 30, 2025 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer